5-amino-N-(3-chlorophenyl)-2-hydroxybenzamide | 1041612-72-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-amino-N-(3-chlorophenyl)-2-hydroxybenzamide
• CAS: 1041612-72-9
• 化学式: C₁₃H₁₁ClN₂O₂
• 分子量: 262.696
• InChiKey: HJNLRZXETPUFHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  75.4
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-amino-N-(3-chlorophenyl)-2-hydroxybenzamide 、 丙烯酰氯 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 5-(Acryloylamino)-N-(3-chlorophenyl)-2-hydroxybenzamide
  参考文献：
  名称：

  Acryloylamino-salicylanilides as EGFR PTK inhibitors

  摘要：

  A series of acryloylamino-salicylanilides were synthesized as inhibitors of EGFR PTK. A strategy of pseudo six-membered ring formed through intramolecular hydrogen bonding in salicylanilides is employed to mimic the planar pyrimidine ring of quinazoline EGFR inhibitors. Acrylamido moiety is incorporated to target the Cys-773 of EGFR specifically. Some of the obtained compounds exhibited good activity as EGFR inhibitors. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.06.088
• 作为产物：
  描述：

  5-硝基水杨酸 在 镍 氢气 、 三氯化磷 作用下， 以 甲醇 、 甲苯 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 生成 5-amino-N-(3-chlorophenyl)-2-hydroxybenzamide
  参考文献：
  名称：

  Acryloylamino-salicylanilides as EGFR PTK inhibitors

  摘要：

  A series of acryloylamino-salicylanilides were synthesized as inhibitors of EGFR PTK. A strategy of pseudo six-membered ring formed through intramolecular hydrogen bonding in salicylanilides is employed to mimic the planar pyrimidine ring of quinazoline EGFR inhibitors. Acrylamido moiety is incorporated to target the Cys-773 of EGFR specifically. Some of the obtained compounds exhibited good activity as EGFR inhibitors. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.06.088

文献信息

• Methods and compositions for the treatment of pain, inflammation and cancer
  申请人：Barbosa Joseph

  公开号：US20080194557A1

  公开（公告）日：2008-08-14

  This invention relates to methods of treating, managing and preventing pain, inflammation, cancer, and ocular diseases and disorders, and to compounds and pharmaceutical compositions useful in such methods.

  本发明涉及用于治疗、管理和预防疼痛、炎症、癌症和眼部疾病和障碍的方法，以及在这些方法中有用的化合物和制药组合物。
• Methods and compositions for the treatment of body composition disorders
  申请人：Barbosa Joseph

  公开号：US20080200458A1

  公开（公告）日：2008-08-21

  This invention relates to methods of treating, managing and preventing body composition disorders, and to compounds and pharmaceutical compositions useful in such methods.

  本发明涉及治疗、管理和预防身体组成失调的方法，以及在这些方法中有用的化合物和制药组合物。
• PROCESS FOR DYEING IN THE PRESENCE OF OXIDATION BASES COMPRISING AT LEAST ONE SULFONIC, SULFONAMIDE, SULFONE, AMID OR ACID GROUP AND A METAL CATALYST, DEVICE AND READY-TO-USE COMPOSITION
  申请人：L'OREAL

  公开号：US20160143826A1

  公开（公告）日：2016-05-26

  The present invention relates to a process for dyeing human keratin fibres, in which use is made of one or more metal catalysts and a composition (A) comprising: (a) at least 10% by weight of one or more fatty substances, (b) one or more oxidation bases of formula (I) or (II), the addition salts thereof, solvates thereof and mixtures thereof: Formula (I), Formula (II) (c) one or more chemical oxidizing agents other than atmospheric oxygen. The invention also relates to a multi-compartment device and to a composition comprising all of the above-mentioned ingredients.
• US9872822B2
  申请人：——

  公开号：US9872822B2

  公开（公告）日：2018-01-23
• [EN] METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER<br/>[FR] MÉTHODES ET COMPOSITIONS UTILISÉS DANS LE TRAITEMENT DE LA DOULEUR, DE L'INFLAMMATION ET DU CANCER
  申请人：LEXICON PHARMACEUTICALS INC

  公开号：WO2008089307A2

  公开（公告）日：2008-07-24

  [EN] This invention relates to methods of treating, managing and preventing pain, inflammation, cancer, and ocular diseases and disorders, and to compounds and pharmaceutical compositions useful in such methods.
  [FR] Cette invention porte sur des méthodes de traitement, de gestion et de prévention de la douleur, de l'inflammation, du cancer et de maladies et troubles oculaires, ainsi que sur des composés et des compositions pharmaceutiques utilisées dans ces méthodes.